Lymphokine‐activated Killer Induction and Its Regulation by Macrophages in Malignant Pleural Effusions

Yanagawa, Hiroaki; Sone, Saburo; Nii, Akihiko; Fukuta, Katsuyuki; Nakanishi, Mie; Maeda, Kenichi; Honda, Mitsuo; Ogura, Takeshi

doi:10.1111/j.1349-7006.1989.tb01658.x

Cited by 19 publications

(19 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our previous investigations showed that approximately 80% of lymphocytes in malignant pleura! effusions before therapy consisted of CD3' cells, and that intrapleural injections of lL-2 resulted in increase in number of T lymphocytes [26]. suggesting that IL-2-aetivated T lymphocytes may contribute to the augmented levels of IL-6 after IL-2 infusions.…”

Section: Discussionmentioning

confidence: 99%

“…The recent finding that tumour cells themselves produce IL-6 also indicates the possibility that a responseofthelungcancereells to IL-2 may have contributed to the observed increase of IL-6. All our patients with a clinical response to IL-2 showed that the lung cancer cells in the efTusions disappeared within 5 days [26]. Thus, it is unlikely that (/; livn induction of lL-6 on IL-2 infusion was produced by the lung cancer cells in the effusions.…”

Section: Discussionmentioning

confidence: 99%

“…In vivo IL-2-aetivated killer induction of lymphocytes in malignant pleural effusions was previously found to be associated with subsequent disappearance of cancer cells from the effusion within i week [26]. IL-6 wns recentiy found to promote differentiation of cyiotoxic T eells [31].…”

Section: Discussionmentioning

confidence: 99%

“…and ibat daily intrapleural administration of lL-2( 1000 U/day) was effective for inducing LAK activity in lymphocytes in pleural effusions in association with rapid disappearance of cancer cells from ihe effusions [26]. Therefore, we injccled rIL-2 al a daily dose of 1000 U/person for 14 days into the pleural caviiy through a Silicone-coatcd.…”

Section: Intrapleural Administration Of Il-2mentioning

confidence: 99%

See 3 more Smart Citations

IL-6 in malignant pleural effusions and its augmentation by intrapleural instillation of IL-2

Yanagawa

Sone

Munekata

et al. 1992

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYThe levels and activities of endogenous IL-6 in malignant pleura! effusions due to lung cancer before and during daily intrapleural instillations of reeombinant IL-2 were examined by enzyme immunoassay and bioassay using an IL-6-dependenl murine hybridoma cell line MH60.BSF2. Before therapy, malignant pieural effusions contained various levels of IL-6. Daily intrapteural instillation of recombinani lL-2 for treatment of malignant pleurisy resulted in significant augmentation of the levels and activities of IL-6 in the pleura! effusions. On fractionation of the pieural effusion by chromatography. one major peak ofmateria! with a mo!, wi of 24 k D showed lL-6 activity. In contrast, no significant level of tumour necrosis factor-alpha or IL-I/J was delectable in pieural effusions before or during local IL-2 therapy. These data suggest that IL-2 is an important regulatory factor of secondary IL-6 producUoti.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Intrapleural Administration Of Il-2mentioning

confidence: 99%

See 2 more Smart Citations

IL-6 in malignant pleural effusions and its augmentation by intrapleural instillation of IL-2

Yanagawa

Sone

Munekata

et al. 1992

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…respectively. as described previously (Sone et al 1987: Yanagawa et al 1989). The resultant MNCs (105 per well) were incubated in CRPMI-1640.…”

Section: Methodsmentioning

confidence: 99%

Comparative analysis of interleukin 15 and interleukin 2 for induction of killer activity and of type 2 cytokine production by mononuclear cells from lung cancer patients

Takeuchi

Yanagawa²,

Suzuki³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

Summary Interleukin (IL) 15 is a novel cytokine with IL-2-like activity. In this study, we examined the effect of IL-15 on induction of non major histocompatability complex (MHC)-restricted killer activity and of type 2 cytokine production by peripheral blood and pleural mononuclear cells (MNCs), from 34 lung cancer patients and 20 control subjects. Interleukin 15 (IL-15) is a novel M 15 000 cmtokine and has similar biological activities to those of IL-2: it induces T-cell proliferation. enhances natural killer (NK) cell cytotoxicity and up-regulates production of NK cell-derived cytokines (Carson et al. 1994). Recently. attention has been focused on the clinical application of IL-15 for cancer immunotherapy (Gamero et al. 1995) and. for effective clinical application of IL-15. at least two problems must be solved. We have already demonstrated that the presence of a malignant neoplasm affects various host functions (Sone et al. 1990: Nabioullin et al. 1995. Therefore. the first problem is whether the presence of lung cancer affects the induction of non-major histocompatibility complex (MHC)-restricted killer activity by 1L-15.The second problem is to evaluate type 2 cytokine production by IL-15-activated mononuclear cells (MNCs). because the growth of cancer cells is regulated by the cytokine network. via autocrine and paracrine pathways. in situ. In the analysis of the cytokine network. two distinct cytokine patterns generated by T lymphocytes can be considered (Mosmann et al. 1986 (Yamamura et al. 1993: Kharkvitch et al. 1994). Production of type 2 cytokines by lung cancer has been reported (Hung et al. 1995). and immunotherapy with cytokines may alter this type 2 predominant pattern of the type 1/type 2 axis.In this work. we studied the effect of L-15 alone or in combination with L-12 on the immune function of MNCs from lung cancer patients. in terms of expression of non-MHC-restricted killer activity and type 2 cytokine production. MATERIALS AND METHODSPatients with lung cancer and control patients Thirty-four patients with primary lung cancer were studied after obtaining informed consent. Of these. 24 were men and ten were women aged 36-83 years (median age 67 years). Histological examinations revealed that 17 patients had adenocarcinoma. nine had squamous cell carcinoma. five had small-cell carcinoma and three had large-cell carcinoma. Staging examination revealed that 17 patients were stage IV. ten were stage IIIB. four were stage I11A. two were stage H and one was stage I. Nine patients had malignant pleural effusion. They had received no anti-cancer therapy before this study. Twenty subjects were studied as controls. Of these. nine subjects were control patients (three males and six females) aged 22-82 years (median age 42 years). Examinations revealed no malignant lesions or autoimmune diseases in these nine patients. The other 11 control subjects (nine men and two women) were healthy volunteers who had no signs of infection. were not taking medication and were aged 22-48 years (median age 28 ye...

show abstract

Interleukin (Il-)15 Has Less Activity Than Il-2 to Promote Type 2 Cytokine Predominance in Tumour-Associated Mononuclear Cells From Lung Cancer Patients

et al. 2001

View full text Add to dashboard Cite

Lymphokine‐activated Killer Induction and Its Regulation by Macrophages in Malignant Pleural Effusions

Cited by 19 publications

References 21 publications

IL-6 in malignant pleural effusions and its augmentation by intrapleural instillation of IL-2

IL-6 in malignant pleural effusions and its augmentation by intrapleural instillation of IL-2

Comparative analysis of interleukin 15 and interleukin 2 for induction of killer activity and of type 2 cytokine production by mononuclear cells from lung cancer patients

Interleukin (Il-)15 Has Less Activity Than Il-2 to Promote Type 2 Cytokine Predominance in Tumour-Associated Mononuclear Cells From Lung Cancer Patients

Contact Info

Product

Resources

About